TPM3::NTRK1

Xenia Parisi1, Anindita Ghosh1, Wei-Lien Wang2

  • 1Department of Hematopathology, The University of Texas MD Anderson Cancer Center Division of Pathology and Laboratory Medicine, Houston, TX, USA.

概括

一种罕见的状细胞肉瘤与NTRK1基因融合重复超过20年后. 使用larotrectinib的向治疗导致了40个月的缓解期,突出了这些儿科瘤的NTRK抑制剂.